Context

Air Liquide entered into exclusive negotiations to acquire a controlling block of 70.49% of LVL Médical's share capital from the Lavorel family concert and other controlling shareholders. Simultaneously, the Lavorel family repurchased LVL Médical's German subsidiary for €80 million, such that Air Liquide's acquisition perimeter is limited to the French activities only. The transaction is subject to clearance from the French competition authority. Air Liquide intends to maintain continuity in LVL Médical's management.

Target

Orkyn (ex LVL Medical) is a leading French home healthcare services provider, recognised as one of the historical and most established players in this segment in France. The company specialises in the management of chronic disease patients at home, providing medical equipment, respiratory therapy devices, and follow-up services on medical prescription. Its service offering covers key pathologies including chronic obstructive pulmonary disease (COPD), sleep apnoea, and diabetes — conditions that require long-term, recurring home-based medical monitoring and equipment. Orkyn had built a strong operational infrastructure across France, with a nationwide network enabling patient coverage in both urban and rural areas.